Navigation Links
Tengion to Present at UBS Global Life Sciences Conference
Date:9/14/2011

EAST NORRITON, Pa., Sept. 14, 2011 /PRNewswire/ -- Tengion, Inc. (NASDAQ: TNGN), a leader in regenerative medicine, today announced that Brian Davis, Vice President Finance and Chief Financial Officer of Tengion, will present at the upcoming UBS Global Life Sciences Conference on Monday, September 19, 2011, at 1:30 pm EDT.

A live webcast of the presentation can be accessed under "Calendar of Events" in the Investors section of the Company's website at www.tengion.com or by accessing http://cc.talkpoint.com/ubsx001/091911a_im/?entity=83_URMMK62.  Investors interested in listening to the live webcast should log on before the start time in order to download any software required.  A replay of the presentation will be available.

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications.  An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal.  The Company's lead preclinical candidate is the Neo-Kidney Augment, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure.  Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment for the treatment of neurogenic bladder.  Tengion has worldwide rights to its product candidates.


'/>"/>
SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion to Present at Rodman & Renshaw 13th Annual Healthcare Conference
2. Tengion Provides Business Update and Reports Second Quarter 2011 Financial Results
3. Tengion Announces Leadership Transition
4. Tengion Provides Business Update and Reports First Quarter 2011 Financial Results
5. Tengion to Host Conference Call to Provide a Business Update and Report First Quarter 2011 Financial Results on May 12, 2011
6. Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel
7. Tengion To Host Conference Call To Provide a Business Update and Report Fourth Quarter 2010 Financial Results on March 25, 2011
8. Tengion Announces Pricing of $31.4 Million Private Placement
9. Tengion Addresses Recent Trading Activity in its Common Stock
10. Tengion to Present at the 13th Annual BIO CEO & Investor Conference and the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
11. Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... and GREENWICH, Conn. , ... investment firm focused on venture growth investments in ... of Josh Richardson , M.D. to Managing ... in biotechnology companies.  He is a board observer ... roles in Longitude,s investments in Aimmune Therapeutics, Akebia ...
(Date:2/16/2017)... 16, 2017  ArmaGen, Inc., a privately held ... treat severe neurological disorders, today reported preliminary evidence ... the company,s investigational therapy for the treatment of ... type I, or MPS I). The initial results ... presented today at the 13 th annual ...
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , February 16, 2017 ... the infusion of innovative telemedicine application, new and ... that are experiencing a boom worldwide. The healthcare ... advancement of technologies, services and new therapies for ... RQHTF) (TSX-V: RHT), Cellectar Biosciences, Inc. (NASDAQ: ...
Breaking Biology Technology:
(Date:2/8/2017)... YORK , Feb. 7, 2017 Report Highlights ... The ... should reach $11.4 billion by 2021, growing at a compound ... Includes - An overview of the global markets for synthetic ... 2015, estimates for 2016, and projections of compound annual growth ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
(Date:2/2/2017)... -- EyeLock LLC, a market leader of iris-based identity authentication ... You Should Know About Biometrics in the Cloud ."  ... a growing concern. In traditional schemes, cryptography is used ... schemes such as username/password suffer from inherent weaknesses. ... elegant solution to the problem of high-security user authentication. ...
Breaking Biology News(10 mins):